Because unstable angina has always been considered a contraindication for dobutamineatropine stress echocardiography (DSE), the role of dobutamine-atropine stress echocardiography in unstable angina is unknown. Our aim was to assess the safety and prognostic value of dobutamine-atropine stress echocardiography in unstable angina.
Introduction
Dobutamine-atropine stress echocardiography (DSE) has emerged as a very useful and cost effective noninvasive test for the diagnosis of coronary artery disease in patients unable to exercise [1] . It has also been used for risk stratification in patients undergoing non-cardiac surgery [2] and early after myocardial infarction [3] , as well as in patients with chest pain or stable angina [4, 5] . Finally, it has also successfully been used for detection of myocardial viability [6] . Unstable angina has always been considered a relative contraindication for dobutamine-atropine stress echocardiography performance, as dobutamine increases cardiac work and myocardial oxygen demands, thus increasing the risk of developing myocardial infarction. Therefore, experience of dobutamine-atropine stress echocardiography in this setting is scarce.
Other non-invasive tests performed after patients have been stabilized, such as treadmill stress test or dypiridamole nuclear scintigraphy, provide useful prognostic values in unstable angina [7] . However, since some patients are not able to exercise or do not tolerate dypiridamole, dobutamine-atropine stress echocardiography appears to be a good alternative for risk stratification in unstable angina considering how useful and safe it has proven to be in other settings such as early after an acute myocardial infarction. Therefore, we performed a prospective study to determine the feasibility and prognostic value of dobutamine-atropine stress echocardiography for risk stratification early after an acute episode of unstable angina.
Methods

Patient selection
Patients included in the study were those admitted to hospital because of unstable angina, defined as typical chest pain at rest, new onset (less than 1 month) exertional angina of at least Canadian Cardiovascular Society (CCS) classification class III in severity, or recent progressive angina (Braunwald class B angina) [8] . In addition, the last episode of chest pain must have occurred within 12 h before admission. Eligible patients were those who remained asymptomatic under medical treatment following the first 48 h after hospital admission. Exclusion criteria were an increase in creatin kinase and CK-MB plasma levels twice the normal upper limit, evidence of pulmonary oedema on admission, recurrent angina during the 48 h after admission, or persistent signs of severe ischaemia in the ECG (symmetrical negative T waves >0·3 mV in three or more contiguous leads), post-myocardial infarction angina or Braunwald class C unstable angina (myocardial infarction within the preceding 2 weeks), secondary angina or Braunwald class A unstable angina, and finally, the presence of concomitant severe cardiac or non-cardiac disease (life expectancy less than 1 year).
Patient management
All patients were treated with aspirin, heparin and antianginal drugs if no contraindication existed. Patients performed a treadmill stress test following a modified Bruce's protocol, or if unable, they underwent dypiridamole nuclear scintigraphy. Nuclear imaging was added to the treadmill stress test when the basal ECG was abnormal (pacemaker, left bundle branch block or extensive Q waves or ST segment abnormalities). An echocardiogram to assess left ventricular function was also performed. Patients underwent coronary arteriography if clinically indicated. Clinical decisions were taken at the discretion of the attending physician who was overseeing the test results. Dobutamine-atropine stress echocardiography results for ischaemia were not available to the attending physician and were not revealed until further analysis had been carried out.
Dobutamine stress echocardiography
Patients who fulfilled the inclusion criteria underwent dobutamine-atropine stress echocardiography within 48 h after admission. Antianginal drugs, including betablocker and calcium channel blocking agents as well as heparin and aspirin, were not stopped before the test. Dobutamine-atropine stress echocardiography was performed following a modified McNeill's protocol [9] . An intravenous line was obtained and blood pressure and ECG were recorded and continuously monitored. A basal echocardiogram was obtained and dobutamine was infused, starting at a dosage of 10 g . kg 1 . min 1 and increasing by 10 g . kg 1 . min 1 . When the target heart rate was not reached, no wall motion abnormalities developed and in the absence of contraindications, a 1 mg bolus of atropine was injected and repeated up to a maximal dosage of 2 mg if necessary. A twodimensional echocardiogram was monitored throughout the procedure, and quad-screen cine-loop images (parasternal long-axis, parasternal short-axis, apical four-chamber and apical two-chamber views) were obtained and recorded on video tape. Causes of test interruption were: development or worsening of wall motion abnormalities, 85% of maximum age-predicted heart rate, blood pressure >220/110 mmHg, severe chest pain, life-threatening arrhythmia, hypotension (systolic blood pressure <90 mmHg), severe ischaemia on the ECG or intolerable side effects.
Data interpretation
Dobutamine-atropine stress echocardiography exams were analysed during acquisition and reviewed by two experienced observers from the video tape recordings. Regional wall motion was assessed semiquantitatively with a 16-segment model, following the American Society of Echocardiograhy Guidelines [10] . Interpretation was made by consensus of these two echocardiographers unaware of the result of the stress test, nuclear scintigraphy or coronary angiography. The test was considered positive for ischaemia when at least one of the following conditions occurred: (a) a new wall motion abnormality appeared in a region with normal rest function; (b) worsening of rest dyssynergy, not including a change from akinesis to dyskinesis; and (c) a biphasic response of rest dyssynergy, i.e. an initial improvement followed by worsening in segmental wall motion. Failure to develop hyperdynamic motion was not considered as an ischaemic response.
Follow-up
The follow-up period was set at 1 year as most severe complications occur in these patients during the first year [11, 12] . Follow-up data were obtained from telephone interviews and from review of the patient's hospital records. End-points were cardiac death, non-fatal myocardial infarction or recurrent unstable angina after hospital discharge.
Definitions
Cardiac death in hospitalized patients was diagnosed by documentation of significant arrythmias, congestive heart failure or cardiac arrest. Cardiac death was also considered when an unexpected sudden death occurred out of hospital. Non-fatal myocardial infarction was defined as the presence of symptoms and signs of myocardial ischaemia with an increase in plasma cardiac enzyme levels twice the normal upper limit or development of new Q waves on the rest ECG. Recurrent unstable angina was defined as a new episode of ischaemic symptoms requiring further hospitalization or medical evaluation (CCS class III-IV angina), without elevation in plasma cardiac enzymes levels, new Q waves in the ECG or new wall motion abnormalities.
Statistical analysis
Discrete baseline characteristics, clinical outcomes, sensitivity, specificity and accuracy are presented as percentages and analysed using the chi-square test. Continuous variables are expressed as mean value SD and compared by the unpaired two-tailed t test. Multivariate analysis was performed using a stepwise logistic regression analysis. Event-free survival was described using the Kaplan-Meier product limit method, with differences between groups compared with the Log-rank Chi-square statistic. A P value<0·05 was considered statistically significant.
Results
Eligible patients
From August 1996 to March 1997, a total of 290 patients were admitted with unstable angina. One hundred and fifty-eight patients were excluded; reasons for exclusion according to protocol are listed in Table 1 .
Patients excluded from the study were older (P<0·05), were more frequently women (P<0·05), diabetic (P<0·05) or hypertensive (P<0·05) and had more ECG changes on admission (P<0·05).
Finally, 132 patients fulfilled the study's inclusion criteria. Ten out of the 132 patients meeting the inclusion criteria (7%) could not be studied with dobutamine-atropine stress echocardiography because of a poor acoustic image in eight patients (6%), apical thrombus in one patient (0·7%) and a history of sustained ventricular tachycardia in another patient (0·7%). Dobutamine-atropine stress echocardiography was performed in the remaining 122 patients (test feasibility 94%).
Patient characteristics and management
The mean age was 64 12 years (36-89) and 29 were women (24%). Eighty patients (65%) had a previous history of coronary artery disease; 36 (29%) prior myocardial infarction and 44 (36%) angina. Sixteen patients were admitted because of progressive exertional angina (13%) and the other 106 (87%) presented with angina at rest: 77 patients (63%) had angina lasting for more than 20 min and 103 (97%) came to hospital within the first 48 h following onset of symptoms. About 50% of the patients had ECG abnormalities on admission: 60% of them had ST segment depression and 40% T wave inversion. Ninety-six patients (78%) received betablocker therapy; the other patients received nondihydropyridinic calcium channel blockers. All the patients were treated with aspirin and heparin in no contraindication existed; these drugs continued to be administered during dobutamine-atropine stress echocardiography administration (Table 2) . Ninety-two patients (75%) performed a treadmill test and 20 of them (22%) were also studied with nuclear imaging; 24 patients (20%) underwent dypiridamole nuclear scintigraphy.
Dobutamine-atropine stress test
Atropine was injected after dobutamine infusion in 97 patients (79%); it was not given to the other 25 (20%) because of a positive dobutamine-atropine stress echocardiography result for ischaemia (37%), severe hypertension (14%), hypotension (5%), having already reached the target heart rate (34%) and glaucoma (9%). A positive dobutamine-atropine stress echocardiography result for ischaemia was obtained in 27 patients (22%); the other 95 patients (78%) had a negative dobutamine-atropine stress echocardiography result for ischaemia.
Only 12 (10%) patients developed ECG changes during the test; all of them consisted of ST depression. None of the patients showed ST elevation.
No major complications (death, myocardial infarction or life-threatening arrhythmia) occurred during 
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dobutamine-atropine stress echocardiography performance. Side effects occurred in 34 patients (28%) ( Table 3 ), but none of them led to premature test interruption. A sudden increase in blood pressure appeared after atropine administration in nine patients (7%), but it was medically controlled without further complications; most of these patients (78%) had a previous history of hypertension.
Follow-up data
One year follow-up data was obtained in 121 patients (99%). Twenty patients underwent coronary revascularization during hospitalization (11 CABG, 9 PTCA). The decision to perform a revascularization procedure did not always follow standard pre-established guidelines, and some attending physicians preferred revascularization to medical therapy to treat their patients. In order to avoid subjectivity and the consequent bias, patients undergoing revascularization before hospital discharge were therefore excluded from prognostic study data analysis. Thus, 101 patients were analysed for prognostic purposes; 21 of them (20%) had a positive dobutamine-atropine stress echocardiography result while the other 80 patients (80%) had a negative dobutamine-atropine stress echocardiography result for ischaemia. At 1 year follow-up, 16 (13%) patients had suffered cardiac events: two (1·5%) patients had died, two (1·5%) had a myocardial infarction, and 12 (10%) were readmitted because of unstable angina. Among the 21 patients with a positive dobutamine-atropine stress echocardiography, nine (43%) had presented clinical events: two patients had died, one had a myocardial infarction and six were readmitted with unstable angina (positive predictive value 43%); on the other hand, only seven out of 80 patients (8·5%) with a negative dobutamine-atropine stress echocardiography presented clinical events: six of them presented recurrent unstable angina and one had myocardial infarction; there were no cardiac deaths (negative predictive value 91%). Accuracy of the test was 81%. When considering only hard events as end-points at 1 year follow-up, i.e. death and nonfatal myocardial infarction, only one patient with a negative dobutamine-atropine stress echocardiography presented a myocardial infarction during follow-up (negative predictive value 98%). Event-free survival of patients with a negative dobutamine-atropine stress echocardiogram at 1 year was 91% compared to 57% for those with a positive dobutamine-atropine stress echocardiogram (Log Rank 16·59, P<0·0001) (Fig. 1) . Survival without myocardial infarction at 1 year follow-up was 98% for patients with a negative dobutamine-atropine stress echocardiogram compared to 85% for those with a positive dobutamine-atropine stress echocardiogram (Log Rank 7·80, P=0·005) (Fig. 2) . These prognostic values proved to be even better than those obtained with the conventional tests used for risk stratification in unstable angina (treadmill stress test and dypiridamole thallium scintigraphy) in the same population: event-free survival of patients with a negative stress test at 1 year follow-up was 88% compared to 73% for those with a positive stress test (Log Rank 3·19, P=0·07).
Univariate and multivariate analysis
Characteristics of patients according to dobutamineatropine stress echocardiography results are shown in Table 4 . There were no differences in maximum heart rate or blood pressure, or in left ventricular function or target heart rate attainment during dobutamineatropine stress echocardiography. However, wall motion abnormalities developed more frequently in patients who presented angina or ECG changes during the test. Univariate predictors of cardiac events during the following year were history of prior myocardial infarction, left ventricular ejection fraction and a positive dobutamine-atropine stress echocardiography result (Table 5) ; ECG changes on admission but not during dobutamine-atropine stress echocardiography, were also predictive of death or myocardial infarction (P=0·04, data not shown). Multivariate analysis selected as independent predictors of cardiac events: history of prior myocardial infarction, left ventricular dysfunction (ejection fraction <45%) and positive dobutamineatropine stress echocardiography for ischemia (Table 6 ).
Effect of beta-blocker therapy
No difference in basal heart rate after 48 h of treatment or in maximum heart rate during dobutamine-atropine stress echocardiography was found between patients on beta-blocker therapy and those receiving other antianginal drugs (non-dihydropyridines): 62 7 vs 63 8 beats . min 1 (P=ns) and 106 23 vs 111 23 beats . min 1 (P=ns), respectively. However, it was only among patients on beta-blockers that the heart rate increased significantly from 85 28 beats . min 1 to 110 20 beats . min 1 , P=0·03; in those not receiving beta-blockers, atropine did not significantly increase the heart rate. Nevertheless, it was impossible to reach 85% of maximum age-predicted heart rate in spite of atropine injection in 75% of patients on beta-blockers and in 64% of patients on calcium channel antagonists.
Discussion
Our study demonstrates that dobutamine-atropine stress echocardiography in patients with unstable angina who remain asymptomatic after 48 h following hospital admission is feasible and safe, and also shows that it is useful to assess the risk of future cardiac events in this setting.
Chest pain without development of an acute Q-wave myocardial infarction, i.e. without persistent ST segment elevation in the electrocardiogram, is the leading cause of hospital admission in Cardiology Units [13] . Because a wide spectrum of pathophysiological features underlies this similar clinical presentation [14, 15] , a variable risk of 
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future events exists in this heterogeneous group of patients. It is known that the great majority (up to 95%) of patients with unstable angina do not develop myocardial infarction during the short term or the in-hospital period; however, recurrent unstable ischaemic events are common [11, 16] . Since different prognoses exist, risk stratification to identify patients at a higher risk of future events is necessary in order to apply the most suitable treatment and management. Limitations of other non-invasive tests used to identify higher risk patients with unstable angina before hospital discharge, include low sensitivity (exercise electrocardiography) and specificity rates (thallium scintigraphy and dipyridamole thallium scintigraphy), inability to exercise in some patients and, finally, higher costs [17] [18] [19] . Previous studies have shown that dobutamineatropine stress echocardiography is feasible, safe and useful in assessing risk of future cardiac events in other settings [3] [4] [5] 20, 21] . Recently, the prognostic value of exercise echocardiography has also been demonstrated in patients with unstable angina [22] . However, few data about the safety and prognostic value of dobutamineatropine stress echocardiography in patients with unstable angina have been available until now [23] .
Feasibility and safety
The feasibility of dobutamine-atropine stress echocardiography in clinical situations other than unstable angina has already been reported: approximately 5% (6% in our study) of patients have an inadequate acoustic window that precludes the performance of successful dobutamine-atropine stress echocardiography [24] . The safety of dobutamine-atropine stress echocardiography has also been analysed in previous large studies [24, 25] . Side effects occurred in 28% of the patients studied but none of them led to premature test interruption; no major complication during dobutamine-stress echocardiography occurred in our study. The most frequent side effects of dobutamine-stress echocardiography are hypotension and arrhythmia [24, 25] . In our study, palpitation and arrhythmia (non-sustained ventricular tachycardia and supraventricular arrhythmia) were also the most frequent cardiac side effects; however, hypertension was much more common than hypotension (7·5% vs 1·5%, respectively). Activation of peripheral alpha-1 adrenergic receptors and dynamic left ventricular cavity obliteration due to strong inotropic stimulation have been proposed as the most important causes of hypotension during dobutamine-atropine stress echocardiography [26] . All patients in the study were on beta-blocker or calcium channel blocker therapy, perhaps avoiding the development of left ventricular outflow tract obstruction, and therefore, averting a higher incidence of hypotension.
The relatively high rates of hypertensive response during dobutamine-atropine stress echocardiography in our study may be explained by the high prevalence of systemic hypertension in our population, as reported by Lee et al. [27] . This sudden hypertensive response was always seen after atropine administration, suggesting that an acute increase in sympathetic tone after parasympathetic blockade may account for these reactions in susceptible hypertensive patients. Therefore, it may be that atropine should be administered in these hypertensive patients more progressively after dobutamine infusion.
The most frequent side effect in our study was facial paresthaesia, which was always well tolerated and never led to test interruption. Finally, recent data suggest that platelet activation may occur during dobutamine infusion [28] , although we did not study platelet function before and after dobutamine-atropine stress echocardiography, none of the patients in the study presented clinical recurrence of angina in the hours following dobutamine infusion; more than 90% of them were on aspirin and heparin. However, more studies are necessary to establish the role of dobutamine in platelet activation and its clinical impact.
Prognostic value
In this study dobutamine-atropine stress echocardiography was shown to be capable of identifying patients with unstable angina at a higher risk of future death or myocardial infarction, and moreover, to identify those with a lower risk of future cardiac events; accuracy of the test was also good (81%). Probability of future cardiac events among unstable angina patients with a negative result for ischaemia is very low (negative predictive value 91%); this prognostic significance is well maintained over the long term. Nevertheless, and as previously reported [29] , this implies a high rate of falsepositive tests in this population. Therefore, dobutamineatropine stress echocardiography may not be as accurate, in terms of prognostic value, as it is in detecting coronary artery disease due to the relative low-tomoderate risk of the present unstable angina population and to the heterogeneity of the underlying coronary anatomy.
These prognostic values are similar to those reported for other non-invasive tests used for risk stratification in unstable angina [8, [17] [18] [19] and even greater than those obtained in the same study population with these tests (see above). Even though dobutamine stress testing using only ECG proved to be accurate to diagnose coronary artery disease in a heterogeneous group of patients with angina [30] , ECG changes during dobutamine-atropine stress echocardiography did not predict prognosis in our study.
With the increasing proportion of elderly or concomitant diseased people, a large number of patients are unable to perform adequate exercise testing, mainly because of deconditioning or neurological, respiratory, peripheral vascular or orthopedic limitations; therefore an exercise-independent test for risk stratification and diagnosis is a very useful choice. Dobutamine-atropine stress echocardiography can be performed at the patient's bedside without any major complications, or the need for heavy devices or special radiation protection. Additionally, dobutamine-atropine stress echocardiography is particularly attractive in terms of health care costs as it is cheaper. Finally, valve disease and ventricular function, the latter also being an independent predictor of outcome in this population, can be assessed with dobutamine-atropine stress echocardiography at the same time as risk stratification.
Role of beta-blocker. The atropine factor
In some studies with dobutamine-atropine stress echocardiography, beta-blocker or calcium channel blocking agents were withheld before dobutamineatropine stress echocardiography performance [25] . In other studies where antianginal drugs were not withheld, the proportion of patients on beta-blockers was substantially less than in our study [1, 3, 24] . On the other hand, the effect of beta-blockers on the accuracy of the test has remained controversial. Our study was not designed to compare accuracy between patients treated with betablockers and those who were not, and indeed, did not have enough power to do so. Nevertheless, the accuracy of dobutamine-atropine stress echocardiography to identify risk of further cardiac events was good in spite of higher rates of beta-blocker treated patients.
It has been proved that atropine administration after dobutamine infusion increases sensitivity of dobutamine echocardiography without any loss in specificity [31] , especially in those patients taking beta-blockers [32] . In our study, and as previous studies have shown [23, 25] , atropine administration was more frequent in patients on beta-blockers, and this was associated with higher maximum heart rates. Therefore, the atropine factor seems most important in these settings where betablocker withdrawal before the test may become impractical or really hazardous.
Study limitations and clinical implications
Since patients included in our study represented a lowto-moderate risk population, a selection bias could not be avoided. Therefore, the number of events during follow-up was low and mainly consisted of unstable angina. The exclusion of patients who had undergone revascularization avoided subjectivity, but on the other hand, led to a lower rate of subsequent cardiac events.
Although other authors have examined similar patient populations, albeit as a subset of larger studies, ours is one of the first to demonstrate the safety of the test in the setting of unstable angina. Secondly, these results give further evidence that a negative result for ischaemia is a strong predictor of a good outcome in the shortand long-term. Finally, the safety and the prognostic
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implications of dobutamine-atropine stress echocardiography demonstrated in this study provide consistent evidence that a non-invasive non-expensive test, such as dobutamine-atropine stress echocardiography can be used early in unstable angina, allowing early discharge from hospital -highly desirable in the current era of health care cost containment.
Conclusions
This study demonstrates that dobutamine-atropine stress echocardiography is a feasible, safe and useful exercise-independent test for risk stratification in unstable angina. It can be performed safely at an early stage, identifying those patients at low risk. This is important in terms of health care costs as it may allow early discharge from hospital. The prognostic value of dobutamine-atropine stress echocardiography for risk stratification in patients with unstable angina was good and similar to other tests used for the same purpose, in spite of beta-blocker therapy and low rates of target heart rate attainment. New technical developments to improve endocardial border definition [33, 34] , may further optimize the already demonstrated prognostic capability of dobutamine-atropine stress echocardiography.
